Literature DB >> 31086606

Efficacy of intravenous lidocaine in improving post-operative nausea, vomiting and early recovery after laparoscopic gynaecological surgery.

Tao Wang1, Hui Liu2, Jian Hong Sun1, Lin Wang1, Jian You Zhang1.   

Abstract

Post-operative nausea and vomiting (PONV) is a major peri-operative complication. It has numerous adverse consequences that seriously affect the post-operative recovery of patients. The aim of the present study was to investigate the efficacy of intravenous lidocaine in improving PONV and recovery after laparoscopic gynaecological surgery. A total of 40 patients were randomly assigned to 2 groups: Group L (lidocaine group) and Group C (control group). The patients in Group L received intravenous lidocaine throughout the operation, while patients in Group C were given a saline infusion. Vital signs, recovery time, extubation time, dosage of remifentanil, first flatus time and defecation time of each patient were recorded. The incidence of PONV after surgery was also recorded. The recovery of the patients was evaluated by using the quality of recovery score (QoR-40). The total dose of remifentanil was significantly lower in Group L (P<0.05). However, the recovery time and extubation time were shorter in Group C (P<0.05). The first flatus time and defecation time were longer in Group C (P<0.05). The mean arterial pressure and heart rate in Group L were lower and more stable (P<0.05). At 6 h after surgery, the incidence of PONV was significantly lower in Group L vs. that in Group C (P<0.05). The QoR-40 score in Group C was significantly lower at 1 and 3 days after the operation compared with that in Group C (P<0.05). In conclusion, intravenous lidocaine administered to patients undergoing laparoscopic gynaecological surgery may reduce PONV and supports their early recovery [trial registration number in Chinese Clinical Trial Registry: ChiCTR-IOR-17010782 (March 5, 2017)].

Entities:  

Keywords:  anaesthesia; intravenous; laparoscopy; lidocaine; post-operative nausea and vomiting

Year:  2019        PMID: 31086606      PMCID: PMC6489080          DOI: 10.3892/etm.2019.7497

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  6 in total

1.  Bacillus coagulans TBC169 probiotics for the recovery of intestinal function after gynecological laparoscopic surgery: a randomized, placebo-controlled trial.

Authors:  Zhihong Li; Zhaobo Guan; Niuniu Bai; Ya Yan; Zhanqin Niu; Juan Xu; Weiqi Gao; Weihong Chen
Journal:  Int J Clin Pharm       Date:  2022-07-27

Review 2.  Intravenous Infusion of Lidocaine Can Accelerate Postoperative Early Recovery in Patients Undergoing Surgery for Obstructive Sleep Apnea.

Authors:  Chenglan Xie; Qiao Wang
Journal:  Med Sci Monit       Date:  2021-02-02

3.  Effects of different thermal insulation methods on the nasopharyngeal temperature in patients undergoing laparoscopic hysterectomy: a prospective randomized controlled trial.

Authors:  Guanyu Yang; Zefei Zhu; Hongyu Zheng; Shifeng He; Wanyue Zhang; Zhentao Sun
Journal:  BMC Anesthesiol       Date:  2021-04-05       Impact factor: 2.217

4.  Genetic Susceptibility Toward Nausea and Vomiting in Surgical Patients.

Authors:  Yvonne Gloor; Christoph Czarnetzki; François Curtin; Béatrice Gil-Wey; Martin R Tramèr; Jules A Desmeules
Journal:  Front Genet       Date:  2022-01-31       Impact factor: 4.599

5.  Effects of Lidocaine on Motor-Evoked Potentials and Somatosensory-Evoked Potentials in Patients Undergoing Intraspinal Tumour Resection: Study Protocol for a Prospective Randomized Controlled Trial.

Authors:  Hongli Yue; Man Zhou; Yingzi Chong; Miao Cheng; Hui Qiao; Yu Lu; Weihua Cui
Journal:  J Pain Res       Date:  2022-02-02       Impact factor: 3.133

6.  Effects of lidocaine, dexmedetomidine, and their combination infusion on postoperative nausea and vomiting following laparoscopic hysterectomy: a randomized controlled trial.

Authors:  Siqi Xu; Shengbin Wang; Shenghong Hu; Xia Ju; Qing Li; Yuanhai Li
Journal:  BMC Anesthesiol       Date:  2021-08-04       Impact factor: 2.217

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.